Stephen Thompson
Partner @ Brandon Capital
Melbourne, Australia
Stephen Thompson is a founding Partner of Brandon Capital Partners. Previously Stephen worked with Bio Innovation SA and helped establish Terra Rossa Capital, a dedicated life science Fund Manager in Adelaide. Prior to this Stephen was a Director of Apax Partners a leading international private equity group based in London. During thistime Stephen was also a Director of Imperial Innovations, the commercialisation company of Imperial College London. Before joining Apax Partners, Stephen fulfilled roles in product development with UK biotechnology company Cantab Pharmaceuticals. Earlier, Stephen spent ten years as a research immunologist in London and California. Stephen is a Member of the Board of Directors at Elastagen P/L, MiReven P/L, Vaxxas P/L, Helmedix P/L, Auspherix P/L and Council Member of the Australian Venture Capital Association Limited (AVCAL). Stephen has an Honours degree in Immunology and Biochemistry, a Ph.D. in Immunology from Kings College London and an MBA, specialising in Entrepreneurship, from Imperial College London. Stephen is a Graduate of the Australian Institute of Company Directors and a Member of AusBiotech.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Stephen Thompson invests in
Stages Stephen Thompson invests in
Countries Stephen Thompson invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 5 (63%)
- Health Care 3 (38%)
- Medical Device 2 (25%)
- Medical 1 (13%)
- Software 1 (13%)
Stage
- Series A 3 (38%)
- Seed 2 (25%)
- Venture - Series Unknown 2 (25%)
- Series D 1 (13%)
Country
- Australia 3 (38%)
- United States 1 (13%)
- United Kingdom 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| OncoRes Medical develops an imaging technology to provide intraoperative information available to surgeons to assist with the identification of tumor and healthy tissue.OncoRes Medical is an early-stage medical device company located in Perth, Western Australia and is developing the patent-protected technology in collaboration with leadingresearchers at the University of Western Australia and the Harry Perkins Institute of Medical Research and breast cancer surgeons at the Western Australian public health system.With funding provided by the Medical Research Commercialisation Fund (MRCF), OncoRes Medical aims to develop the technology for use in clinical applications that require the real-time assessment of tissue microstructure. | $19.2M / Venture - Series Unknown / Feb 12, 2026 | ||
| Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia. | $31.8M / Series D / Aug 25, 2025 | ||
| Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases. | $115.3M / Series A / Jul 08, 2024 | ||
| OncoRes Medical develops an imaging technology to provide intraoperative information available to surgeons to assist with the identification of tumor and healthy tissue.OncoRes Medical is an early-stage medical device company located in Perth, Western Australia and is developing the patent-protected technology in collaboration with leadingresearchers at the University of Western Australia and the Harry Perkins Institute of Medical Research and breast cancer surgeons at the Western Australian public health system.With funding provided by the Medical Research Commercialisation Fund (MRCF), OncoRes Medical aims to develop the technology for use in clinical applications that require the real-time assessment of tissue microstructure. | $6.6M / Series A / May 18, 2022 | ||
| Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases. | $5.9M / Seed / Nov 16, 2020 | ||
| Longas Technologies, a Next Generation Sequencing (NGS) technology developer, has provided details on its Morphoseq™ library prep and associated software technology at the ‘Sequencing, Finishing and Analysis. | Venture - Series Unknown / May 16, 2019 | ||
| QurAlis is a operator of a biotechnology company intended to discover and develop potential precision therapeutics for amyotrophic lateral sclerosis (ALS). The company focuses on the link between genetics and disease in ALS and other neurological diseases, enabling doctors to successfully treat ALS . | $5.5M / Seed / Nov 19, 2018 | ||
| Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia. | $10.1M / Series A / Aug 02, 2011 |
Co-Investors
About Brandon Capital
Brandon Capital Partners is a funds management business aiming to generate quality returns for Australia's leading superannuation funds by investing in innovative life science ventures. Our team works with entrepreneurs to build businesses, creating value for the entrepreneurs, their teams and our investors.
Brandon Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Chris Nave
Partner, Managing Director & Co-Founder
|
|||
Robert Daniels
Venture Partner
|
|||
|
Stephen Thompson
Partner
|
|||
Bob Soh
Senior Investment Manager
|
|||
Christopher Smith
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Stephen Thompson invest in?
Stephen Thompson invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series A and Seed stage. Most of the 8 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Stephen Thompson?
Public channels for Stephen Thompson include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Stephen Thompson last invest?
The most recent investment recorded for Stephen Thompson closed in Feb 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
